Pharmacist Tony Sacco will examine the emerging evidence on GLP (Glucagon-Like Peptide-1) receptor agonists and their role in lowering cardiovascular risk, enhancing metabolic health, and aiding long-term heart protection. This session will cover: How GLP-1 medications affect cardiovascular pathways, reduce major events, impact blood pressure, cholesterol, inflammation, and endothelial health. Important for people with heart disease, diabetes, or obesity. Clinicians learn about long-term cardiac protection. Emerging research in cardiometabolic medicine.
